Table of Contents

Premium Company Profile: Discovery Laboratories - Detailed profile of Discovery Laboratories including corporate strategy, value chain presence and SWOT Analysis

Product Code: dbhc0044

Publication Date: 20-Nov-2007

---

Overview

Introduction

Discovery Labs' main focus is to discover and develop novel drugs for the treatment of respiratory diseases. The company has proprietary surfactant technology known as Surfactant Replacement Therapies (SRT) that is used to produce a series of respiratory therapies for patients in the Neonatal Intensive Care Unit, Pediatric Intensive Care Unit, critical care unit and other hospital settings.

Scope

· Contains corporate strategy, value chain presence and SWOT Analysis

· Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors

· Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Report Highlights

Discovery Labs is focused on the discovery and development of proprietary surfactant technology as Surfactant Replacement Therapies (SRT) for the treatment of respiratory disorders and diseases. In April 2006, the company received a second Approvable Letter from the FDA for Discovery Labs' lead product candidate.

Discovery Labs did not record any revenues during the fiscal year 2006, primarily due to the restructuring of its corporate partnership with Esteve in late 2004. Prior to 2006, the company's sole contributor to revenue growth during 2002-2005 was licensing.

Discovery Labs' sole contributor to sales growth out to 2010 will be the sales of Surfaxin. Revenues from Surfaxin is expected to increase to $58 million in 2010, representing an absolute growth of +$58 million during the period 2006-2010.

Reasons to Purchase

· Access all the important information and analysis on the company in a single report

· Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain

· Gain access to company's adjusted five year financial data along with key ratios and market capitalization

---

Overview	1
Catalyst	1
Summary	1
Table of Contents	2
Table of figures	3
Table of tables	4
Company Structure	5
Company Overview and Key Facts	5
Business Description	6
Landmark Products and Services	6
Surfactant Replacement Technology	6
History	7
Locations and Subsidiaries	9
Company Financials	10
Stock Market Performance	10
P&L	12
Balance Sheet	14
Cash Flow	14
Business Segment Performance	16
Products & Services	17
Pipeline Products	17
Collaboration Pipeline	17
Surfaxin	17
Aerosurf	17
Aerosolized SRT	18
AC Forecast Product Sales	19
Competitors and Strategic Business Relationships	21
Key Competitors	21
Key Suppliers	21
Shareholding Structure	23
Strategy	24
Company View	24
Corporate Strategy	25
SWOT Analysis	27
Overview	27
Strengths	28
Surfactant replacement technology	28
Surfaxin	28
Weaknesses	29
Continued losses	29
Lack of experience in marketing	29
Opportunities	30
Aerosurf	30
Threats	31
Intense competition	31
Healthcare reforms	31
Value Chain Analysis	32
Overview	32
Discovery and Product Development	32
Manufacturing	33
Scorecard	34
Overview	34
Scorecard Analysis	35
Key Employees	36
List of Key Employees	36
Key Employee Biographies	37
Robert J Capetola	37
W Thomas Amick	37
Antonio Esteve	37
Max Link	37
Herbert H McDade	38
Marvin E Rosenthale	38
John G Cooper	38
David L Lopez	38
Kathryn Cole	39
Charles F Katzer	39
Thomas F Miller	39
Gerald J Orehostky	39
Robert Segal	40
Mary B Templeton	40
Financial and Operational Overview	41
Financial and Operational Overview	41
APPENDIX	44
Ask the analyst	44
Datamonitor consulting	44
Disclaimer	44
List of Figures
Figure 1: Discovery Laboratories - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)	13
Figure 2: Discovery Laboratories - Key Strategic Revenues, 2006-2010 ($ Mn)	20

---